Compare AbbVie Inc (ABBV) vs Paychex, Inc. (PAYX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Paychex, Inc. — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while Paychex, Inc. trades at $106.21 (market cap $38.44B). The key difference: AbbVie Inc is far larger — about 11.7× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.4%). Which is the better fit depends on your goals.
| ABBV | PAYX | |
|---|---|---|
Market Cap | $449.91B | $38.44B |
Sector | Health | Industrials |
52-Week High | $261.07 | $147.99 |
52-Week Low | $184.85 | $85.57 |
Enterprise Value | $513.38B | $41.92B |
Dividend Yield | 2.72% | 4.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Paychex (PAYX) trades at $108.12, up 1.66% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI suggests mild overbought conditions. Fundamentally, the company maintains robust profitability with 27% net margins and 44.8% ROE, supported by steady revenue growth and strong cash flow generation.
The outlook remains positive with analyst consensus at $110 target and continued AI-driven growth initiatives. However, elevated valuation multiples and potential macroeconomic headwinds to small business hiring present risks. The stock offers a compelling combination of growth execution and shareholder returns through dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
